Łącki S, Wyżgolik K, Nicze M, Georgiew-Nadziakiewicz S, Chudek J, Wdowiak K. Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report. World J Clin Cases 2021; 9(18): 4859-4865 [PMID: 34222459 DOI: 10.12998/wjcc.v9.i18.4859]
Corresponding Author of This Article
Stanisław Łącki, Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia, Reymonta 8, Katowice 40-027, Silesian Voivodeship, Poland. s.lacki@outlook.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2021; 9(18): 4859-4865 Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4859
Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report
Stanisław Łącki, Kinga Wyżgolik, Michał Nicze, Sylwia Georgiew-Nadziakiewicz, Jerzy Chudek, Kamil Wdowiak
Stanisław Łącki, Kinga Wyżgolik, Michał Nicze, Jerzy Chudek, Kamil Wdowiak, Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia, Katowice 40-027, Silesian Voivodeship, Poland
Sylwia Georgiew-Nadziakiewicz, Imaging and Isotope Diagnostics Department, Chorzów General Hospital, Chorzów 41-500, Silesian Voivodeship, Poland
Author contributions: Chudek J and Wdowiak K collected the clinical data; Wyżgolik K, Nicze M and Łącki S designed the case report, reviewed the literature and drafted the manuscript; Georgiew-Nadziakiewicz S performed and interpreted the positron emission tomography-computed tomography imaging; Chudek J and Wdowiak K critically reviewed the manuscript; All authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Stanisław Łącki, Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia, Reymonta 8, Katowice 40-027, Silesian Voivodeship, Poland. s.lacki@outlook.com
Received: February 8, 2021 Peer-review started: February 8, 2021 First decision: April 4, 2021 Revised: April 13, 2021 Accepted: May 6, 2021 Article in press: May 6, 2021 Published online: June 26, 2021
Core Tip
Core Tip: Follicular lymphoma is an indolent lymphoma requiring immunochemotherapy with rituximab. This anti-CD20 monoclonal antibody depletes malignant and normal B-cells, resulting in a significantly increased risk of infectious complications, including the novel coronavirus, severe acute respiratory syndrome coronavirus 2 infection [coronavirus disease 2019 (COVID-19)]. We present the first case of mild COVID-19 in an elderly patient during ongoing follicular lymphoma treatment, without significant deterioration after rituximab administration. This case highlights that rituximab-based therapy may have no evident negative effect on the clinical course of COVID-19 in patients with follicular lymphoma, which may be significant during the current pandemic.
